FDA approves taletrectinib for ROS1-positive non-small cell ...
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small ...
ROS1+ NSCLC Therapy | IBTROZI™ (taletrectinib)
INDICATION IBTROZI ™ (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC).
Nuvation Bio Inc. - U.S. Food and Drug Administration ...
Jun 11, 2025 · NEW YORK-- (BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, …
FDA Approves Talectrectinib (Ibtrozi) for ROS1-Positive Lung ...
On June 11, 2025, the U.S. Food and Drug Administration (FDA) approved taletrectinib (Ibtrozi), a new targeted therapy for adults with locally advanced or metastatic ROS1-positive non-small …
IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available ...
Jun 11, 2025 · While NSCLC is the most common form of lung cancer, ROS1+ accounts for approximately 1-2% of those cases, according to the American Lung Association. ROS1+ …